Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer

To the Editor Criss et al¹ report the results of a cost-effectiveness analysis comparing durvalumab consolidation therapy with no consolidation therapy for stage III non–small cell lung cancer (NSCLC). Although the analysis offers unique strengths, several model assumptions create doubt about the conclusion that durvalumab consolidation therapy is cost-effective at a willingness-to-pay threshold of $100 000 per quality-adjusted life year.